Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24845250 | 0.95 | HTT (0.71) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL3061121 | 0.94 | HTT (0.69) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL12292255 | 0.94 | HTT (0.69) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL235672 | 0.94 | HTT (0.69) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL5217172 | 0.91 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL968445 | 0.89 | HTT (0.63) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL319161 | 0.88 | HTT (1.00) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL18254066 | 0.87 | HTT (0.81) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL6044833 | 0.87 | HTT (0.76) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL8698925 | 0.86 | HTT (0.80) | HTTLMNASMN1; SMN2TGM2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043829-A1 | CHROMANE CYCLIC AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2026-02-26 | — | — | WO | disclosed |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-7507546-B2 | Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter | XENOPORT, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1235828-B1 | PROCESS AND INTERMEDIATES TO A TETRAHYDRO-[1,8]-NAPHTHYRIDINE | MERCK & CO INC (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-0946165-B1 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1235828-A4 | PROCESS AND INTERMEDIATES TO A TETRAHYDRO-[1,8]-NAPHTHYRIDINE | MERCK & CO INC (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-1235828-A1 | PROCESS AND INTERMEDIATES TO A TETRAHYDRO-[1,8]-NAPHTHYRIDINE | Merck & Co., Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6423845-B1 | CYCLIZATION A 2-AMINO-3-FORMYLPYRIDINE COMPOUND; BONE DISORDERS, OSTEOPOROSIS | MERCK & CO., INC. | 2002-07-23 | — | — | US | disclosed |
| US-6262268-B1 | REACTING 2,5-DI(3-PROPYLAMINO)PYRIDINE WITH BASE IN SOLVENT TO FORM 3-(5,6,7,8-TETRAHYDRO-(1,8)-NAPHTHYRIDIN-2-YL)-PROPYLAMINE AND ISOLATING PRODUCT | MERCK & CO., INC. | 2001-07-17 | — | — | US | disclosed |
| WO-2001038328-A1 | PROCESS AND INTERMEDIATES TO A TETRAHYDRO-[1,8]-NAPHTHYRIDINE | MERCK & CO., INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-0946165-A4 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-0946165-A1 | INTEGRIN ANTAGONISTS | Merck & Co., Inc. (US) | 1999-10-06 | — | — | EP | disclosed |
| US-5952341-A | VITRONECTIN RECEPTOR ANTAGONISTS FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING RESTENOSIS, DIABETIC RETINOPATHY, TUMOR, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION | MERCK & CO., INC. (US) | 1999-09-14 | — | — | US | disclosed |
| WO-1998018460-A1 | INTEGRIN ANTAGONISTS | MERCK & CO., INC. (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | HTT 1006/4885LMNA 136/4885SMN1; SMN2 3648/4885 |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | HTT 1006/4885LMNA 136/4885SMN1; SMN2 3648/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | HTT 1006/4885LMNA 136/4885SMN1; SMN2 3648/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | HTT 1006/4885LMNA 136/4885SMN1; SMN2 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.